Indian pharmaceutical stocks have shown resilience in the face of proposed tariffs on generic drugs by US President Donald Trump, as several mitigating factors appear to be keeping investors from hitting the panic button.

Indian drugmakers supply approximately 40% of the generic medicines imported by the United States, making any tariff measures a potentially significant risk for the sector. India is widely recognized as a global hub for generic drug manufacturing, supplying medicines to over 200 countries, and the US is the largest export market for India's pharmaceutical industry. Companies such as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Cipla, Zydus Lifesciences, Aurobindo Pharma, Glenmark Pharmaceuticals, Granules India, and Lupin have substantial exposure to the American market.

However, several factors are tempering investor concern. A delayed rollout of any tariff measures provides the industry with time to adapt. Additionally, many large Indian pharmaceutical companies have already established manufacturing facilities within the United States, which could help offset the impact of import duties on products manufactured in India. The US Food and Drug Administration maintains field offices in India to inspect and oversee production quality, reflecting the deeply integrated regulatory and supply chain relationship between the two countries. The practical challenges of imposing tariffs on low-cost generic medicines — which help reduce healthcare costs for American consumers — also contribute to the measured market response. Pharmaceutical products have historically been treated as a distinct category in trade policy, often receiving different consideration from other manufactured goods in tariff negotiations.

Generic drugs are a cornerstone of the US healthcare system, where they account for roughly 90% of prescriptions filled while representing a small fraction of total drug spending. Replacing Indian generic supply at comparable scale and cost would be difficult, as few other manufacturing bases currently match India's capacity in this segment. Disrupting the supply of affordable generics through tariffs could have downstream effects on drug availability and pricing for patients.

The proposed tariffs remain at an early stage, and the absence of immediate implementation details has allowed Indian pharma stocks to trade without significant disruption so far. Market participants are also watching whether any tariff measures would include exemptions or phased timelines for pharmaceutical products specifically, as has occurred with other sectors in past trade policy actions.

Source: CNBC-TV18